Skip to main content

Table 1 Patient baseline demographics and disease characteristics (FAS)

From: Intravitreal aflibercept for the treatment of patients with neovascular age-related macular degeneration in routine clinical practice in Latin America: the AQUILA study

 

Treatment-naïve (n = 201)

Previously treated (n = 73)

Overall (n = 274)

Age, years

77.6 ± 7.6

76.1 ± 8.3

77.2 ± 7.8

Female, n (%)

135 (67.2)

44 (60.3)

179 (65.3)

Country, n (%)

 Argentina

163 (81.1)

33 (45.2)

196 (71.5)

 Colombia

12 (6.0)

7 (9.6)

19 (6.9)

 Costa Rica

4 (2.0)

14 (19.2)

18 (6.6)

 Mexico

22 (11.0)

19 (26.0)

41 (15.0)

BCVA in the study eye, letter score

48.2 ± 23.5

47.7 ± 21.4

48.0 ± 22.9

Categorical BCVA letter score, n (%)

  ≥ 70 letters

42 (20.9)

14 (19.2)

56 (20.4)

  < 70 letters

159 (79.1)

59 (80.8)

218 (79.6)

CRT, μm

378 ± 137

400 ± 137

385 ± 137

  1. Values are mean ± SD unless otherwise stated
  2. BCVA best-corrected visual acuity, CRT central retinal thickness, FAS full analysis set, SD standard deviation